Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic crossover study of compounded chenodeoxycholic acid capsules
NL-OMON49918Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of chenodeoxycholic acid in cerebrotendinous xanthomatosis (CTX) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Pharmacokinetic parameters of compounded versus commercial chenodeoxycholic acid. Started Sep 2022; status: active, not recruiting.
02
Drugs
chenodeoxycholic acid
03
Conditions
cerebrotendinous xanthomatosis (CTX)
Beyond the preview
Go deeper on NL-OMON49918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49918.